SCHEMBL14905375

SCHEMBL14905375

COc1ccc2ncc(-c3cccnc3)cc2n1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 4/20 0.60
PDGFRA P16234 4/20 0.60
CYP2A6 P11509 2/20 0.54
EGFR P00533 1/20 0.50
FGFR1 P11362 2/20 0.49
FGFR2 P21802 2/20 0.49
FGFR4 P22455 2/20 0.49
FGFR3 P22607 2/20 0.49
KDR P35968 2/20 0.49
PDE2A O00408 1/20 0.49
PDE10A Q9Y233 1/20 0.49
CYP19A1 P11511 4/20 0.48
CYP11B2 P19099 4/20 0.48
CYP11B1 P15538 3/20 0.48
CYP17A1 P05093 2/20 0.48
NTRK1 P04629 1/20 0.44
CSF1R P07333 1/20 0.44
NTRK2 Q16620 1/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14905405 0.84 PDGFRB (0.60) PDGFRBPDGFRAEGFRFGFR1FGFR2
SCHEMBL7264558 0.81 CYP11B2 (0.64) PDGFRBPDGFRACYP2A6FGFR1KDR
SCHEMBL1422588 0.78 CYP19A1 (0.65) PDGFRBPDGFRACYP2A6CYP19A1CYP11B2
SCHEMBL14905376 0.78 CYP2A6 (0.60) PDGFRBPDGFRACYP2A6EGFRFGFR1
SCHEMBL14905530 0.78 PDGFRB (0.61) PDGFRBPDGFRACYP2A6EGFRFGFR1
SCHEMBL14905514 0.76 FGFR3 (0.52) PDGFRBPDGFRACYP2A6FGFR1FGFR2
SCHEMBL8170900 0.75 PDGFRB (1.00) PDGFRBPDGFRACYP2A6EGFR
SCHEMBL28138821 0.75 CYP2A6 (0.67) PDGFRBPDGFRACYP2A6EGFRCYP19A1
SCHEMBL14905216 0.73 FGFR3 (0.60) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL14905511 0.73 PDE10A (0.48) PDGFRBPDGFRAPDE2APDE10ACYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2776436-B1 NEW COMPOUNDS ASTEX THERAPEUTICS LTD (GB) 2019-03-13 EP disclosed
US-9757364-B2 Naphthyridine derivative compounds ASTEX THERAPEUTICS LTD (GB) 2017-09-12 US disclosed
US-9757364-B2 Naphthyridine derivative compounds ASTEX THERAPEUTICS LTD (GB) 2017-09-12 US disclosed
US-20170105978-A1 NEW COMPOUNDS ASTEX THERAPEUTICS LIMITED (GB) 2017-04-20 US disclosed
US-20170105978-A1 NEW COMPOUNDS ASTEX THERAPEUTICS LIMITED (GB) 2017-04-20 US disclosed
US-9527844-B2 Naphthyridine derivative compounds ASTEX THERAPEUTICS LIMITED (GB) 2016-12-27 US disclosed
US-9527844-B2 Naphthyridine derivative compounds ASTEX THERAPEUTICS LIMITED (GB) 2016-12-27 US disclosed
US-20160108034-A1 NAPHTHYRIDINE DERIVATIVE COMPOUNDS ASTEX THERAPEUTICS LIMITED (GB) 2016-04-21 US disclosed
US-9309241-B2 Naphthyridine derivative compounds ASTEX THERAPEUTICS LTD (GB) 2016-04-12 US disclosed
US-9309241-B2 Naphthyridine derivative compounds ASTEX THERAPEUTICS LTD (GB) 2016-04-12 US disclosed
US-20150057293-A1 NEW COMPOUNDS ASTEX THERAPEUTICS LIMITED (GB) 2015-02-26 US disclosed
US-20150057293-A1 NEW COMPOUNDS ASTEX THERAPEUTICS LIMITED (GB) 2015-02-26 US disclosed
WO-2013061077-A1 NEW COMPOUNDS ASTEX THERAPEUTICS LIMITED (GB) 2013-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150057293-A1 NEW COMPOUNDS NQO1, NTPCR, NDC1 PDGFRB 3569/4885PDGFRA 3281/4885CYP2A6 424/4885
US-20170105978-A1 NEW COMPOUNDS NQO1, NTPCR, NDC1 PDGFRB 3569/4885PDGFRA 3281/4885CYP2A6 424/4885
US-20160108034-A1 NAPHTHYRIDINE DERIVATIVE COMPOUNDS NQO1, NDC1, NTPCR PDGFRB 3222/4885PDGFRA 2879/4885CYP2A6 464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.